Suchergebnisse - "Dvorkin, Mikhail"

PubPharm (8)

1

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer : The ASTRUM-005 Randomized Clinical Trial

enthalten in: JAMA | 2022

von Cheng, Y. | Han, L. | Wu, L. | +106

CommentIn: JAMA. 2022 Sep 27;328(12):1205-1207. - PMID 36166047

2

Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2022

von Edelman, M. | Dvorkin, M. | Laktionov, K. | +20

3

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck : a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Lee, N. | Ferris, R. | Psyrri, A. | +18

CommentIn: Lancet Oncol. 2021 Jul;22(7):e290. - PMID 34197752

4

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : updated results from a randomised, controlled, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Goldman, J. | Dvorkin, M. | Chen, Y. | +123

CommentIn: Lancet Oncol. 2021 Mar;22(3):e83. - PMID 33662291

5

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN) : a randomized, controlled, open-label, phase III study

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2020

von Goldman, J. | Garassino, M. | Chen, Y. | +17

6

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : a randomised, controlled, open-label, phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Paz-Ares, L. | Dvorkin, M. | Chen, Y. | +122

CommentIn: Lancet. 2019 Nov 23;394(10212):1884-1885. - PMID 31590987

7

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer : JAVELIN Gastric 100 study design

enthalten in: Future oncology (London, England) | 2019

von Moehler, M. | Ryu, M. | Dvorkin, M. | +19

8

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses : A Phase 2 Randomized Clinical Trial

enthalten in: JAMA oncology | 2018

von Montagut, C. | Argilés, G. | Ciardiello, F. | +29

ErratumIn: JAMA Oncol. 2019 May 1;5(5):745. - PMID 31070664

1
[1]